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David M Shaw recently published a critique of our Health
Technology Assessment (HTA) on homoeopathy in this
journal [1], which calls for a response. We expected a sci-
entific debate to ensue on our chosen research methods and
were surprised to be confronted with a biased mixture of
false or incomplete citations, wrong matches and, as a con-
sequence, incorrect conclusions that reveal a lack of famili-
arity and experience with both homoeopathy and the Swiss
setting.
We will refute the allegations and rectify misunderstand-
ings, in the order of appearance in Shaw’s text. Because
of numerous repetitions in Shaw’s text we have subsumed
some of the allegations thematically:
Background
The HTA was prepared within the framework of PEK
(“Programm Evaluation Komplementärmedizin” [Comple-
mentary Medicine Evaluation Programme]), which was
launched by the Swiss Federal Office of Public Health
(SFOPH) in 2005 [2, 3] and comprised several pre-defined
project-parts, e.g., prospective observational studies, sys-
tematic literature reviews, meta-analyses and HTAs. Each
project covered a part of the whole PEK-project, and it was
intended that the HTA would cover aspects which were not
addressed by the other parts.
Recently, a positive public vote in Switzerland for includ-
ing complementary medicine in the constitution (19 May
2009) led to restricted provision by certified doctors within
the statutory Swiss health insurance from 1 January 2012
until 31 December 2017 [4].
Coverage of complementary medicine provided by non-
medical practitioners through private medical insurance is
independent of the decision of the Swiss electorate.
Accountability
Shaw, “In 2011 the Swiss government published a report
on homoeopathy.“
Reply: Although the original HTA-report was shown for
some time on the homepage of the BSV/BAG (part of
SFOPH), neither the German booklet of the HTA report
[5] nor the English summarised version [6] or the English
translation of the report [7] were published by SFOPH. The
report was prepared on behalf of SFOPH by the PanMedi-
on Foundation, Zurich, as contractor with participation of
external experts.
Non-scientific conduct
In his paper Shaw analyses the report and concludes that it
is scientifically, logically and ethically flawed. […]
HTA
Shaw, “HTA normally conducts new research.”
Reply: A short glance at existing HTA reports contradicts
this statement: A review of more than 1,000 HTA-reports
from about 15 countries all over the world revealed that
“All agencies consider data from published RCTs as pre-
ferred evidence base” [8]. The observation that in HTAs
mainly a retrospective approach is used is also supported
by another analysis [9], which reports that in more than
90% of HTAs, literature review is the chosen method of
assessment. Randomised Controlled Trials (RCTs) are the
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gold-standard of study design for a methodologically
defined setting and therefore deliver mainly information
about the efficacy of the technology under investiga-
tion. Health technology assessment goes beyond this as-
pect, as it should also provide information about the effects
of a technology in the “real world” [10]. Therefore, both
aspects were taken into account by the inclusion of other
study designs. This HTA followed pre-defined criteria: [7,
p48ff, references p 66]: (ECHTA 2001, BSV 2001, DIMDI
2004, INHTA 2001, Heusser 2001) which, in addition,
were specifically designed for the Swiss evaluation of com-
plementary medicine by the SFOPH well in advance of
the PEK-project [11]. Inclusion of study designs other than
RCTs into comparative effectiveness research is accepted
by other international HTA agencies, e.g., Scotland. [12,
Chapter 5, p 11: “Clinical effectiveness” in the context of
medicinal product assessment]. Apart from these method-
ological aspects, we would like to point out that this HTA
was prepared within the framework of PEK which also in-
cluded prospective observational research with published
results [2, 3].
RCT
Shaw, “[...] RCT is the ‘gold standard’ [...]”
Reply: RCT, the “gold standard …” focuses on internal
validity – and has never been validated for therapeutic sys-
tems like homoeopathy, especially concerning clinical ef-
fectiveness and cost-effectiveness. SFOPH therefore pre-
pared a model that is better suited to the population's needs
in terms of external validity, i.e., the non-experimental
“real world” situation [11]. Today, this procedure is re-
ferred to as HIA (Health Impact Assessment).
The SFOPH’s Manual for the Standardisation of Clinical
and Economic Evaluation of Medical Technologies [10],
on which our assessment is also based, explicitly mentions
as appropriate test methods those which
a) Evaluate the treatment method under consideration in
its entirety
b) Take into proper consideration the realistic research
possibilities in practice
c) Permit inference to the target population that is being
treated in practice
It is obvious from the terminology (“entirety”, “in prac-
tice”) that RCTs do not comply with these three require-
ments.
Further reservations towards RCTs that we outlined in our
HTA (chapter 5, pp 28ff) were:
1. The absence of a positive or any RCT result is no proof
of ineffectiveness (“absence of evidence is not
evidence of absence”, Altman and Bland 1995).
2. A negative RCT result is also not valid proof of
ineffectiveness because many factors can be involved
in causing false-negative RCT results.
3. Individualised medical care is more and more being
replaced by standardised treatment methods to ensure
comparability and reproducibility of study outcomes.
4. Trial results can be significantly positive even though
only a small percentage of patients experience genuine
benefit from the trial.
5. Reproducibility is surprisingly low even with “hard”
RCTs (rigorous inclusion criteria, end points with
minimal subjectivity).
6. There needs to be genuine openness (“equipoise”) at
the beginning of a randomised trial, i.e., neither
physician nor patient have a preference regarding a
particular treatment. The fact that a patient has given
his or her “informed consent” does not avoid the
problem (of absent equipoise), since the responsibility
cannot simply be placed on the patient, certainly not
according to the Declaration of the World Medical
Association.
7. In view of the ethical problems mentioned, it appears
doubtful whether the authorities have the right to insist
on randomised trials, i.e. evidence of inferior treatment
and discrimination of control group patients, as a basis
for decisions concerning health service
reimbursement.
8. Different professional evidence-based reviews of
identical clinical studies can arrive at different
conclusions and even opposing recommendations on
treatment. Not only the RCT results but also the results
obtained from systematic reviews of RCTs can show
considerable divergence.
9. The thematic orientation of RCTs is often not relevant
to problems of health care or the needs of patients, but
is driven by subjective interests (career, sponsors).
Shaw, “Rather than accepting that the scientific method
shows that homoeopathy is ineffective, and accepting this,
they argue that the method itself is flawed and create their
own method to produce the answers they want.”
Reply: Shaw is quite wrong here and seems to stumble
right into the trap that Altman and Bland warned against:
“Absence of evidence is not evidence of absence” [13].
Even if Shaw sees the effectiveness of homoeopathy as not
proven, there are no scientific studies that prove that it is
not effective.
Having considered all arguments we state, “In clinical stud-
ies, taking internal and external validity criteria into ac-
count, the effectiveness of homoeopathy can be seen as
clinically evident, and certified application as safe. From a
methodological point of view the evidence of homoeopath-
ic effectiveness is all the more remarkable if one considers
that in most research studies basic rules of classical homoe-
opathy were violated.”
Literature search
Shaw, “They did not conduct an online review.”
Reply: This statement is simply not true. Chapter 6 (pp
47ff) exactly describes the search strategies, searched data-
bases (mainly online databases) used in the report and re-
lated results. Additional handsearching of other sources
like journals and reference lists of relevant retrieved art-
icles is a well-accepted approach, which is also recommen-
ded by the Cochrane collaboration [14]. The rationale for
study selection is given in detail in chapter 10 (p 128).
Concerning the literature search, Shaw presumes also that
the “... use of expert contacts” suggests biased and “inform-
al methodology”. The consideration of expert opinions was
intended within the PEK approach because the specific
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situation in Switzerland should be reflected. Consulting ex-
perts is a well-accepted practice within the HTA process,
e.g., in Germany [15]. It is a matter of course that experts
did not influence the assessment itself, but made their ex-
pertise available.
Reinterpretation of results
Shaw, “The report re-interprets Kleijnen’s famous study
and argues that its conclusions were only negative because
the authors believed that the mechanism of homoeopathy
was implausible. Given their acceptance (based on laborat-
ory tests) that homoeopathy is plausible, the authors argue
that this means the results of the original study were posit-
ive.”
Reply: It is correct that we didn’t follow all conclusions of
included studies (see also table 9.6. of our HTA, p. 116,
where deviations are given in detail). There were two main
reasons for different assessments in this HTA compared to
the original authors’ conclusions:
1. The results were achieved by “vote counts”, e.g., “5
studies were negative, 4 positive, which results in a
negative result” and
2. Original authors’ conclusions were based on criteria
which we refused for good reasons or which were
external (inappropriate, off topic), e.g., Kleijnen et
al.’s conclusion: “The amount of positive evidence
even among the best studies came as a surprise to us.
Based on this evidence we would be ready to accept
that homoeopathy can be efficacious, if only the
mechanism of action were more plausible.” We
concluded: “As their reservations are only based on
the plausibility issue, […], we do not accept it and the
result in favour of the effectiveness of homoeopathy
stands.”
Assessment
Shaw, “It is also ethically suspect to conclude that homoe-
opathy is safe when no review was conducted. The authors
state that ‘a systematic search for cases in the homoeopath-
ic and legal literature was not possible owing to problems
of infrastructure, methodology and time.’ The authors did
not even mention the issues of potential harm to patients
who choose homoeopathy rather than effective convention-
al treatment. […]“
Reply: The first sentence is not true. Safety issues were part
of the PEK project and were dealt with in our HTA as well
(chapter 11, pp 159ff). The second sentence reads as fol-
lows in the HTA, “A systematic search for individual cases
(single cases, ‘Einzelfälle’) in the homoeopathic and legal
literature was not possible owing to problems of infrastruc-
ture, methodology and time.” (No emphasis in the original
text). We furthermore pointed out in 11.4 (p 161) that “Ho-
moeopathic physicians […] act in accordance with the gen-
eral guidelines of medical responsibility”; so no essential
medical treatment will be kept from patients.
Conflict of interest
Shaw: “The majority of the report’s authors are homeo-
paths. ... Homeopaths believe that homoeopathy works, and
as such have an inherent conflict of interest. ... Even if they
are capable of objectivity, they have an obligation to de-
clare this as a potential conflict of interest. ... Being homeo-
paths themselves, they clearly had a strong interest in pro-
ducing a report that might motivate the Swiss government
to rule that homoeopathy will in future be covered by the
Swiss health insurance system…”
Reply: Familiarity and, whenever possible, personal ex-
perience of the subject-matter are prerequisites of a trust-
worthy report. Systematic search and scientific analyses for
this HTA were conducted exclusively by independent con-
tractors. Of course, we collected information from experi-
enced experts in homoeopathy (any other approach would
have been careless and non-scientific). We felt no necessity
to make a statement of conflict of interest, particularly as
we gave full and frank disclosure of contributors, including
CV details, interests and allegiances in Chapter 15. Noth-
ing there renders it inappropriate for any of us to have
undertaken this research work, as Shaw himself appears
to acknowledge: “Of course, the fact that someone is a
homeopath does not mean they cannot be objective about
homoeopathy” [1]. We defined and substantiated our meth-
odology, and applied it consistently.
We recognised the undoubted risk of bias, of which we
were always mindful of, but considered it to be outweighed
by the gain of expert knowledge of the subject of investig-
ation. As a matter of course the experts consulted did not
influence the assessment of systematically searched studies
as such, but made their expertise available (mainly) in the
form of relevant sources for systematic information retriev-
al and consultation on the selection of relevant therapies
(e.g., the categorisation of homoeopathic approaches) and
relevant outcomes (rather than surrogate parameters).
Comparison with UK Report to the
House of Commons Science and
Technology Committee
Reply: In this letter to the editor we refrain from discussion
of the House of Commons Science and Technology Com-
mittee report. This has already been done by others [16].
Conclusion
In conclusion we state that the article by David Martin
Shaw constitutes an accumulation of false claims, indefens-
ible allegations and defamatory remarks without any justi-
fication in content. In our opinion, Shaw’s article and the
arguments contained therein do not in any way meet the
minimum requirements of a scientific paper. The author ap-
pears to have found it necessary to misrepresent or distort
facts and attack the authors of the Swiss Report with unten-
able allegations and defamatory statements in order to sup-
port his belief of the ineffectiveness of homoeopathy. His
allegations are clearly refuted by our counter-statement.
We protest against the accusation that the Swiss Report was
a ‘case of research misconduct’. David M. Shaw appears
to attack homoeopathy, using pseudoscientific arguments
and flouting intellectual integrity and honesty in a way that
goes beyond the realm of scientific work.
Having considered all arguments we state: In clinical stud-
ies, taking internal and external validity criteria into ac-
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count, effectiveness of homoeopathy can be seen as clinic-
ally evident, and certified application as safe.
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